Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash (an aggregate of ...

The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin will further expand Lilly's global parenteral (injectable) product manufacturing ...

3 янв. 2024 г. · US drug manufacturer Eli Lilly has completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.

8 июл. 2024 г. · Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory ...

19 авг. 2024 г. · Eli Lilly has concluded the acquisition of Morphic Holding at $57 per share, bolstering its inflammatory bowel disease portfolio.

8 июл. 2024 г. · The acquisition is valued approx. $3.2b and is set to support development of oral integrin therapies for conditions like ulcerative colitis.

15 авг. 2023 г. · The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company's product ...

3 окт. 2023 г. · Eli Lilly is snapping up Point Biopharma Global, acquiring the radiopharmaceutical cancer company for $1.4 billion.

27 авг. 2024 г. · Eli Lilly and Company (Lilly) completed its acquisition of Morphic Holding, a biopharmaceutical company developing oral integrin therapies ...